InvestorsHub Logo
Followers 49
Posts 4894
Boards Moderated 0
Alias Born 02/05/2016

Re: attilathehunt post# 666955

Thursday, 01/25/2024 12:05:00 PM

Thursday, January 25, 2024 12:05:00 PM

Post# of 695440

Immunomedics, Inc. acquired by Gilead Sciences for $8.4 billion in 2020: This translates to a staggering 1,062% premium over Immunomedics' closing share price just before the acquisition news broke. The deal was driven by Gilead's interest in acquiring Trodelvy, Immunomedics' lead drug for treating triple-negative breast cancer.



Haha, what?

Gilead paid a 108% premium for Immunomedics. And they paid $21B, not $8.4 billion. And Gilead ran a campaign to drive the Immuno price up to a point where the value would be approvable at 108%.

Damn y'all are bad at this.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News